CMG · Chipotle Mexican Grill, Inc.

Current Thesis

Chipotle Mexican Grill's expansion-led recovery depends on positive third-quarter traffic and a return above the market's 2026-09-02 close of $38.52 by its 2026-10-28 results. The 2026-09-11 adjusted close of $36.20 weakens the September 3 recovery assessment, although it remains above the published $35 structural threshold. A weekly close below $35 invalidates this recovery thesis; negative year-over-year third-quarter transactions would separately reject its demand premise.

The narrative is maturing — the September 2 Seoul opening and September 1 analyst target announcements remain the identifiable expansion catalysts, while the September 11 close is below the September 2 reference close. That classification is an inference from the dated headlines and price observations; participation and fund-flow data are missing. The company still schedules third-quarter results for October 28, beyond the next 30 days. Company earnings announcement, 2026-09-01

Bullish and bearish views on Chipotle Mexican Grill, Inc.

The model's bull view on Chipotle Mexican Grill, Inc. (CMG), in brief: Traffic entered the disruption growing. Chipotle's 2026-07-29 results reported second-quarter comparable restaurant sales growth of 2.2%, including transaction growth of 1.0%. Revenue was $3.348 billion, up 9.3% year over year; these are pre-outbreak demand measurements, not… The bear view: The recovery has lost ground. The adjusted daily close declined from $38.52 on 2026-09-02 to $36.20 on 2026-09-11. The later observation challenges the earlier assessment that outbreak repair was complete; it does not establish renewed deterioration in restaurant demand. Revenue… Both cases follow in full.

Bull Case

• Traffic entered the disruption growing. Chipotle's 2026-07-29 results reported second-quarter comparable restaurant sales growth of 2.2%, including transaction growth of 1.0%. Revenue was $3.348 billion, up 9.3% year over year; these are pre-outbreak demand measurements, not evidence of subsequent recovery.
• Expansion has a dated opening. Chipotle announced its first Asian restaurant in Seoul on 2026-09-02 through a joint venture with Sangmidang Holdings. The opening supplies an observable expansion milestone, although the existing disclosure provides no joint-venture revenue contribution. Company release archive
• Affected product was removed. The Food and Drug Administration (FDA) reports that Chipotle began changing suppliers at affected restaurants on 2026-07-20 and no longer serves the implicated product. Its advisory states that the removal eliminated the ongoing consumer risk from those establishments within this outbreak. FDA investigation advisory, checked 2026-09-13

Bear Case

• The recovery has lost ground. The adjusted daily close declined from $38.52 on 2026-09-02 to $36.20 on 2026-09-11. The later observation challenges the earlier assessment that outbreak repair was complete; it does not establish renewed deterioration in restaurant demand.
• Revenue growth missed earnings growth. The 2026-07-29 release reported second-quarter diluted earnings per share of $0.32, unchanged year over year, while restaurant-level operating margin fell to 25.2% from 27.4%. Negative third-quarter transaction growth would invalidate the demand thesis, and a margin below 25.2% would show further sequential compression.
• The investigation remains open. On the 2026-09-13 check, the FDA advisory still marked the investigation ongoing and displayed an August 21 update. Its August 19 figures remained 431 illnesses across 32 states and 57 hospitalizations; an unchanged published count does not establish restored customer traffic. FDA investigation advisory

Setup & Price Structure

The 2026-09-11 adjusted close was $36.20, with a three-month price increase of 12.3% and a reported distance of 14.5% below the 52-week high of $42.36. The 14-period relative strength index (RSI) was 44.9, compared with 81.6 in the September 2 observation. Momentum has cooled on those readings; the supplied observations are too sparse to establish a new base or a rising moving average.

The $35 threshold retains its September 3 published role as the boundary of the reclaimed August shelf. The September 11 close is above it, but the intervening weekly closes are missing, so an uninterrupted history above that threshold cannot be established. The September 2 close of $38.52 is the recovery reference, not an analyst valuation.

Analyst attention clustered on 2026-09-01: Bank of America raised its target to $53, while Mizuho maintained $43. Baird had lowered its target to $40 on August 24. These dated opinions document disagreement and coverage timing; they do not measure ownership crowding. Current retail participation, insider transactions and issuance data are missing. Benzinga analyst-action record

Catalyst Calendar (next 30 days)

• 2026-09-13 through 2026-10-13: No company-confirmed earnings or other fixed-date thesis catalyst was identified in the reviewed announcements. The September 1 company advisory places the next results outside this window. Company earnings announcement
• 2026-10-28: Third-quarter results are scheduled for approximately 4:10 p.m. Eastern Time, followed by the conference call at 4:30 p.m. Positive year-over-year transactions would support the demand premise; negative transactions would reject it against the second quarter's 1.0% growth. Company announcement, 2026-09-01

What Would Change Our Mind

Loss of the reclaimed August shelf would end the price-recovery case: a weekly close below $35 is the observable break condition retained from the September 3 assessment. Negative year-over-year transactions in the October 28 results would separately invalidate the premise that demand survived the disruption.

The positive resolution requires both a daily close above the September 2 reference of $38.52 by October 28 and positive third-quarter transaction growth. If the date passes without those observations, the recovery case has not met its stated test. The September 11 close of $36.20 and absence of post-outbreak transaction results support a low-conviction forecast.

Correlation Notes

This remains a single-company recovery and expansion thesis. The September 11 price snapshot contains no matched restaurant-peer or index return series, so it supports no measured correlation claim or conclusion that a consumer-sector move explains CMG's recovery.

The FDA advisory identifies Chipotle and QDOBA as recipients of the same implicated supply chain. That establishes a shared operating exposure as of the August investigation, rather than evidence of stock-price correlation. FDA investigation advisory